NEUROBIO - Key Persons
Dave is the former chairman and CEO of Office Depot and former president of Sherwin-Williams Paint Stores. In addition to his role as Chairman Emeritus of SSA & Company, he is a Senior Advisor at Peter J. Solomon Company. He formerly served on the boards of Office Depot, Ryder Transportation, Dicks Sporting Good and others. Dave was appointed on the board by Kairos Ventures as an Investor Director for Neuro-Bio.
Dr Gary Manchee gained his PhD in 1995 studying species differences in drug metabolism and went on to collaborate with the University of Dundee to crystallise a major human phenolsulphotransferase enzyme. Gary is the co-author on 26 published papers. Dr Gary Manchee has been involved in the development of several key medicines including Ventolin, Zantac and Serevent and progressed 35 new compounds into early and late stage development. He has also led cross-discipline research and development teams within cardiovascular and psychiatric disease areas. Dr Gary Manchee has worked in the pharmaceutical industry for over 30 years, starting as a bench scientist and progressing to Director of Drug Metabolism and Pharmacokinetics in Psychiatry, Respiratory & inflammatory, and Immuno-inflammatory disease areas within Drug Discovery at GSK. He has joined Neuro-Bio as CDO
Sara graduated from the University of Barcelona, with a PhD in Neuropharmacology and Drug development. She started her career with Prof Susan Greenfield as a postdoctoral researcher exploring novel approaches to neurodegeneration at Oxford University and has continued this work while transitioning from academia to the private sector. She has considerable experience in research and development and extensive expertise relating to the nicotinic receptor - a main focus for Neuro-Bio.
Job Titles:
- Executive Assistant to Baroness Greenfield
Emily has had a wide range of experience in the service industry, from catering to leisure organisations. Building on this expertise she has then served as Executive Assistant to Baroness Greenfield for the last 10 years.
Javier is a graduate in Law from Complutense University of Madrid and he holds a Master's degree in corporate finance & law from ESADE Business School. His early career started as Financial Advisor and gained a certificate as European Financial Advisor . He worked seven years in a wealth asset management firm as Customer Operation Manager in Spain. Last eight years he has been working in finance in the UK for different industries (environmental ,technology and biotech). Currently he is in the final stage of ACCA to be a chartered certificated accountant in the UK.
Lavinia brings several years of experience in the fast and busy luxury retail industry of Bicester Village, working as Assistant Manager. Developing various tasks through the years, from training new staff members up to Administration, HR, recruitment, and customer care. She has joined the team as Office manager.
Mark holds a Ph.D. in Pharmacology from the University of Bristol, where he completed a "bench-to-bedside" thesis focusing on the mechanisms of new antiplatelet agents. He has over ten years' experience managing wide ranging drug development programs in both academia and industry including running clinical trials and international target discovery programs.
Job Titles:
- Chairman
- Executive Chair of the RSA Group
Nick is Executive Chair of The RSA Group, a global leader in Life Sciences Executive Search and Executive Interims. Serving biotech, pharma, medical devices, diagnostic, and academic medical research markets. He has been a Director of The RSA Group since 1986, joined the business full-time in 1995 and took the helm in 2000. Nick also serves as an Independent Non-Executive Director of an investment company focusing on cannabinoid and Internet-of-Things businesses; an early stage biotech company with a proprietary platform in oncology, anti-infectives and diagnostics, an IT business specializing in healthcare, travel and cybersecurity and an advanced AgriTech business.
Professor Paul Herrling was Head of Corporate Research at Novartis. He is also Chairman of the Board of the Novartis Institute for Tropical Diseases in Singapore, an endeavour to advance medical research in the area of tropical infectious diseases, which historically have received little drug-research funding. Prior to this, Paul Herrling was Head of Global Research at Novartis Pharma and a member of the Pharma Executive Committee (PEC), he is a member of the Board of the Genomics Institute of the Novartis Research Foundation in La Jolla California and he serves on the boards of several other research institutions. Paul Herrling is also Professor of Drug Discovery Science at the University of Basel, Switzerland. He obtained his doctorate in 1975 at the University of Zurich and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA).
Watch Professor Herrling contribute to the Press Conference held on the 5th of April 2022 at the Royal College of Physicians
Tim is a chartered accountant with many years' experience acting as a CFO or Finance Director for a number of different companies in a variety of business sectors. Tim qualified as a chartered accountant in 1991 in London and in the same year he left practice to join The Britt Allcroft Group Limited (subsequently renamed Gullane Entertainment plc) on the South Coast which owned the IP rights over Thomas the Tank Engine. Over the next ten years, he was a key member of the senior management team that floated the media company in 1996 onto the main market of the London Stock Exchange and grew the business significantly thereafter through a mixture of internal growth and a succession of acquisitions including the purchase of Guinness World Records for approximately £45m from Diageo. After leaving Gullane in 2001, Tim worked initially as an independent consultant, advising and in some cases investing in companies in the publishing, IT, telecoms and media sectors. Tim co-founded his own firm of Chartered Accountants (Avonglen Limited) in 2003 with two other partners based on Southampton Science Park and currently provides CFO services to a small portfolio of mainly technology based businesses.
Todd is an accomplished operating executive and entrepreneur, having served as Citigroup CFO for 5
years and as CEO of Citigroup's $10 Billion Global Wealth Management division for 2.5 years. Todd is a